Liver organoid disease model and method for creating it

JP2026143426A5Pending Publication Date: 2026-10-01CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI +1
0 Cites 0 Cited by

Patent Information

Application Number
JP2026078740
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-06-09
Filing Date
2026-05-08
Publication Date
2026-10-01

AI Technical Summary

Technical Problem

Current in vitro models for liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and iatrogenic parenteral nutrition-related liver disease (PNALD), lack the complexity to model common and severe conditions such as epithelial organ fibrosis and inflammation, and existing methods fail to effectively co-develop supporting lineages with epithelial cells, leading to limited therapeutic development.

Method used

A method involving the co-differentiation of pre-fibrotic and inflammatory lineages in liver organoids using a free fatty acid composition, particularly oleic acid, to create a 3D liver organoid model that mimics steatohepatitis and other liver disorders, incorporating RA signaling to influence stromal cell differentiation.

Benefits of technology

The method generates liver organoids that accurately model liver diseases, including NAFLD and PNALD, capturing complex conditions like fibrosis and inflammation, providing a robust platform for drug screening and personalized treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This document provides a method for creating lipotoxic organoid models. [Solution] Disclosed herein is a method for preparing and using lipotoxic organoid models. In certain embodiments, the method may include the step of contacting liver organoids with a free fatty acid (FFA) composition. In one embodiment, the FFA composition may include oleic acid, linoleic acid, palmitic acid, or a combination thereof.
Need to check novelty before this filing date? Find Prior Art